JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. has announced the termination of the development for an expanded indication of TEMCELL HS Inj. for neonatal hypoxic ischemic encephalopathy (nHIE) after a Phase I/II clinical trial showed no significant difference in treatment efficacy. The clinical trial compared standard hypothermia therapy with and without the addition of TEMCELL. This decision is not expected to affect the company’s consolidated business results for the fiscal year.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
